NYSE:BAXBaxter International Stock Price, Forecast & News

Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BAX shares have increased by 9.3% and is now trading at $85.23. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International.

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Baxter International.

Baxter International will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Baxter International Inc (NYSE:BAX) posted its quarterly earnings results on Thursday, April, 30th. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.73 by $0.09. The medical instruments supplier had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.74 billion. Baxter International had a return on equity of 22.70% and a net margin of 8.85%. Baxter International's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.76 earnings per share. View Baxter International's earnings history.

Baxter International announced a quarterly dividend on Tuesday, May 5th. Investors of record on Friday, June 5th will be given a dividend of $0.245 per share on Wednesday, July 1st. This represents a $0.98 annualized dividend and a yield of 1.15%. The ex-dividend date is Thursday, June 4th. This is a boost from Baxter International's previous quarterly dividend of $0.22. View Baxter International's dividend history.

Baxter International declared that its board has authorized a share repurchase plan on Tuesday, November 13th 2018, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 6.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.

20 brokers have issued 12-month target prices for Baxter International's shares. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's stock price to reach $96.60 in the next twelve months. This suggests a possible upside of 13.3% from the stock's current price. View analysts' price targets for Baxter International.

Media coverage about BAX stock has trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Baxter International earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Baxter International.

Baxter International saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,030,000 shares, an increase of 31.3% from the June 15th total of 3,070,000 shares. Based on an average daily volume of 3,100,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the shares of the company are sold short. View Baxter International's Current Options Chain.

Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.03%), Fulton Breakefield Broenniman LLC (0.03%), Envestnet Asset Management Inc. (0.02%), Tsfg LLC (0.02%), Dalton Greiner Hartman Maher & Co. (0.02%) and Diversified Trust Co (0.01%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International.

BAX stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Envestnet Asset Management Inc., State of Alaska Department of Revenue, IFM Investors Pty Ltd, OLD Point Trust & Financial Services N A, Private Trust Co. NA, Farmers & Merchants Trust Co of Chambersburg PA, and Jacobs & Co. CA. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International.

BAX stock was purchased by a variety of institutional investors in the last quarter, including Fulton Breakefield Broenniman LLC, Canandaigua National Corp, DNB Asset Management AS, Everence Capital Management Inc., Carlson Capital Management, Exane Derivatives, NuWave Investment Management LLC, and Gofen & Glossberg LLC IL. View insider buying and selling activity for Baxter International.

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BAX stock can currently be purchased for approximately $85.23.

Baxter International has a market capitalization of $43.23 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

The official website for Baxter International is www.baxter.com.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]